SS Innovations International, Inc. Third Quarter 2025 Financial Results
SS Innovations International, Inc. (NASDAQ: SSII), a pioneering company in developing surgical robotic technologies, recently announced its financial results for the third quarter ending September 30, 2025. The unaudited results reflect substantial growth and strategic advancements in the company's operations.
Third Quarter Highlights
The third quarter of 2025 demonstrated remarkable performance for SS Innovations, continuing the momentum built in previous quarters:
- Revenue surged by 192.5%, reaching $12.8 million compared to $4.4 million in the same period last year.
- Gross profit saw a significant increase of 166.0%, amounting to $6.2 million against $2.3 million from Q3 2024.
- Despite the revenue growth, the net loss was recorded at $3.7 million, consistent with the previous year's loss.
- Installation of the SSi Mantra surgical robotic system increased dramatically, with a total of 27 installations, a 350.0% rise from last year's six installations.
Key Performance Metrics
In addition to the remarkable revenue increases, the company's gross margin was slightly lower at 48.1% compared to 52.8% in Q3 2024. However, the overall financial health remains strong, with no long-term debt reported and cash and cash equivalents reported at $5.7 million, excluding restricted cash.
Performance Over the First Nine Months
When looking at the first nine months of 2025, the company reported:
- A revenue increase of 123.0%, totaling $28.0 million as opposed to $12.5 million during the same period in 2024.
- The gross profit climbed to $13.2 million, up 193.7% from last year's $4.5 million.
- The net loss reduced significantly to $9.7 million, compared to a loss of $17.2 million from the first nine months of 2024.
- SS Innovations installed 63 SSi Mantra systems during the year, highlighting its growing footprint in the medical robotic landscape.
Regulatory Approvals and Market Entry
Dr. Sudhir Srivastava, Chairman and CEO, noted the company's commitment to delivering affordable robotic surgical solutions globally. With regulatory approvals in seven countries, the company is poised for future growth, planning to enter both the U.S. and European markets. A successful human factors validation study was recently completed, paving the way for a 510(k) submission to the FDA.
Highlights from the CEO
Dr. Srivastava remarked on the positive trajectory of the company, emphasizing their leadership in the Indian market and their goal of democratizing access to advanced surgical care. He stated, "The increasing utilization of our SSi Mantra system reflects our dedication to delivering high-quality, cost-effective medical solutions that improve surgical outcomes across diverse patient populations. We are excited about the future as we aim to expand our market presence further and enhance our product offerings."
Recent Innovations and Achievements
This quarter was also marked by several notable achievements, including:
- The successful execution of the world's first pediatric pyeloplasty telesurgery, demonstrating the SSi Mantra's capabilities.
- The appointment of Naveen Kumar Amar as Chief Financial Officer, aimed at strengthening the company's financial strategy.
- Completion of a human factors validation study, deemed essential for the upcoming FDA submission.
Conclusion and Future Outlook
SS Innovations International, Inc. is on a strong growth trajectory, revolutionizing surgical robotics in both established and emerging markets. The financial results from the third quarter and first nine months of 2025 indicate a robust demand for their innovations. As the company navigates toward regulatory approval in key markets, it remains dedicated to expanding its product lines and enhancing access to robotic surgical solutions globally.
Frequently Asked Questions
1. What were SS Innovations' revenue figures for Q3 2025?
In Q3 2025, SS Innovations reported a revenue of $12.8 million, which is a 192.5% increase from the previous year's $4.4 million.
2. How many SSi Mantra systems were installed in the latest quarter?
The company installed 27 SSi Mantra surgical robotic systems in Q3 2025, representing a 350.0% increase from the prior year.
3. What was the net loss reported for the first nine months of 2025?
SS Innovations experienced a net loss of $9.7 million for the first nine months of 2025, which is an improvement over the $17.2 million loss in the same period in 2024.
4. What future plans does SS Innovations have for market expansion?
SS Innovations plans to enter the U.S. and European markets following the completion of regulatory approvals in seven countries.
5. Who is the current CEO of SS Innovations?
Dr. Sudhir Srivastava serves as the Chairman and CEO of SS Innovations, steering the company towards its goals of global expansion and access to advanced surgical technology.
